JoelChasSchererMD

Vice President, Clinical Development. Immunotherapeutics

Dr. Scherer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

45 citations
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
David Monteith, Emily C. Collins, Corinne Vandermeulen, Anne Van Hecken, Eyas Raddad
Frontiers in Pharmacology. 2017-10-17
43 citations
A decade of innovation in pharmaceutical R&D: the Chorus model.
Paul K. Owens, Eyas Raddad, Jeffrey W. Miller, John R. Stille, Kenneth G. Olovich
Nature Reviews. Drug Discovery. 2015-01-01
2 citations
Site of effect of LY2951742 for migraine prophylaxis–Authors' reply
David W. Dodick, Peter J. Goadsby, Egilius L.H. Spierings, Joel C Scherer, Steven Sweeney
The Lancet. Neurology. 2015-01-01

Journal Articles

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placeb...
David W Dodick, Peter J Goadsby, Egilius L H Spierings, Joel C Scherer, Steven P Sweeney, David S Grayzel, Lancet Neurology, 8/11/2014